Floatz logo

Incb099318

Squamous Cell Penile Carcinoma

Incyte CorporationPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Squamous Cell Penile Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Institute of Cancer Research, United Kingdom
Phase 3B
Ifosfamide
Institute of Cancer Research, United Kingdom
Phase 3B
Ipilimumab
National Cancer Institute (NCI)
Phase 2B
Rigosertib
Traws Pharma, Inc.
Phase 2B

View all 14 →

Same molecule, other indications

Incb099318 is also rated in:

PD-L1 Amplified Tumor (9p24.1)Dormant
CC
Indicative ·
43 / 100
View asset →
MSI-H/dMMR TumorsDormant
CC
Indicative ·
43 / 100
View asset →
anal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →